PDCD1 and neoplasm: Although the combination of elraglusib with anti-PD-1 did not appear to significantly reduce the signal as seen by IVIS, the hematoxylin and eosin (H&E) staining does show a clear decrease in tumour size which aligns with the increase in survival as shown in Fig. 4B. This is similar for the sequential treatment; in this case the tumour is more spread than in the combined treatment; however, the intensity of the staining is lower.